



## PRIOR AUTHORIZATION POLICY

**POLICY:** Oncology – Capecitabine Prior Authorization

- Xeloda® (capecitabine tablets – Genentech, generic)

**REVIEW DATE:** 06/18/2025

---

### INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT WHERE APPROPRIATE AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. WHERE COVERAGE FOR CARE OR SERVICES DOES NOT DEPEND ON SPECIFIC CIRCUMSTANCES, REIMBURSEMENT WILL ONLY BE PROVIDED IF A REQUESTED SERVICE(S) IS SUBMITTED IN ACCORDANCE WITH THE RELEVANT CRITERIA OUTLINED IN THE APPLICABLE COVERAGE POLICY, INCLUDING COVERED DIAGNOSIS AND/OR PROCEDURE CODE(S). REIMBURSEMENT IS NOT ALLOWED FOR SERVICES WHEN BILLED FOR CONDITIONS OR DIAGNOSES THAT ARE NOT COVERED UNDER THIS COVERAGE POLICY (SEE "CODING INFORMATION" BELOW). WHEN BILLING, PROVIDERS MUST USE THE MOST APPROPRIATE CODES AS OF THE EFFECTIVE DATE OF THE SUBMISSION. CLAIMS SUBMITTED FOR SERVICES THAT ARE NOT ACCOMPANIED BY COVERED CODE(S) UNDER THE APPLICABLE COVERAGE POLICY WILL BE DENIED AS NOT COVERED. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

## CIGNA NATIONAL FORMULARY COVERAGE:

### OVERVIEW

Capecitabine, a nucleoside metabolic inhibitor with antineoplastic activity, is indicated for the following uses:<sup>1</sup>

- **Breast cancer**, treatment of advanced or metastatic disease:
  - In combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy.
  - As a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated.
- **Colorectal cancer**:
  - Adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen.
  - Perioperative treatment of locally advanced rectal cancer as a component of chemoradiotherapy in adults.
  - Treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen.

- **Gastric, esophageal, or gastroesophageal junction cancer,** treatment of adults with:
  - Unresectable or metastatic disease as a component of a combination chemotherapy regimen.
  - HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen.
- **Pancreatic Cancer,** adjuvant treatment of pancreatic adenocarcinoma as a component of a combination chemotherapy regimen in adults.

## Guidelines

The National Comprehensive Cancer Network (NCCN) Compendium recommends use of capecitabine for the indications listed in the FDA-Approved Indications and Other Uses with Supportive Evidence sections.<sup>2</sup>

## POLICY STATEMENT

Prior Authorization is recommended for prescription benefit coverage of capecitabine. All approvals are provided for the duration noted below.

• **Xeloda® (capecitabine tablets - Genentech, generic)**  
**is(are) covered as medically necessary when the following criteria is(are) met for FDA-approved indication(s) or other uses with supportive evidence (if applicable):**

## FDA-Approved Indications

1. **Breast Cancer.** Approve for 1 year if the patient is  $\geq 18$  years of age.
2. **Colon Cancer.** Approve for 1 year if the patient is  $\geq 18$  years of age.
3. **Esophageal and Esophagogastric Junction Cancers.** Approve for 1 year if the patient is  $\geq 18$  years of age.
4. **Gastric Cancer.** Approve for 1 year if the patient is  $\geq 18$  years of age.
5. **Pancreatic Adenocarcinoma.** Approve for 1 year if the patient is  $\geq 18$  years of age.

## Other Uses with Supportive Evidence

6. **Ampullary Adenocarcinoma.** Approve for 1 year if the patient is  $\geq 18$  years of age.
7. **Anal Carcinoma.** Approve for 1 year if the patient is  $\geq 18$  years of age.

- 8. Biliary Tract Cancer.** Approve for 1 year if the patient is  $\geq 18$  years of age.
- 9. Central Nervous System Cancers.** Approve for 1 year if the patient is  $\geq 18$  years of age.
- 10. Cervical Cancer.** Approve for 1 year if the patient is  $\geq 18$  years of age.
- 11. Endometrial Carcinoma.** Approve for 1 year if the patient is  $\geq 18$  years of age.
- 12. Gestational Trophoblastic Neoplasia.** Approve for 1 year if the patient is  $\geq 18$  years of age.
- 13. Head and Neck Cancers.** Approve for 1 year if the patient is  $\geq 18$  years of age.
- 14. Neuroendocrine and Adrenal Tumors.** Approve for 1 year if the patient is  $\geq 18$  years of age.
- 15. Occult Primary Tumors.** Approve for 1 year if the patient is  $\geq 18$  years of age.
- 16. Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer.** Approve for 1 year if the patient is  $\geq 18$  years of age.
- 17. Penile Cancer.** Approve for 1 year if the patient is  $\geq 18$  years of age.
- 18. Rectal Cancer.** Approve for 1 year if the patient is  $\geq 18$  years of age.
- 19. Small Bowel Adenocarcinoma.** Approve for 1 year if the patient is  $\geq 18$  years of age.
- 20. Squamous Cell Skin Cancer.** Approve for 1 year if the patient is  $\geq 18$  years of age.
- 21. Thymomas and Thymic Carcinomas.** Approve for 1 year if the patient is  $\geq 18$  years of age.
- 22. Vaginal Cancer.** Approve for 1 year if the patient is  $\geq 18$  years of age.
- 23. Vulvar Cancer.** Approve for 1 year if the patient is  $\geq 18$  years of age.

#### **CONDITIONS NOT COVERED**

- **Xeloda® (capecitabine tablets - Genentech, generic)**

**is(are) considered not medically necessary for ANY other use(s); criteria will be updated as new published data are available**

## REFERENCES

1. Xeloda® tablets [prescribing information]. South San Francisco, CA: Genentech; December 2022.
2. The NCCN Drugs & Biologics Compendium. © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on June 11, 2025. Search terms: capecitabine.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	<b>Biliary Tract Cancer:</b> The condition of approval of "hepatobiliary cancer" was changed to "biliary tract cancer".	08/23/2023
Annual Revision	<b>Cervical Cancer:</b> Condition of approval and criteria were added to Other Uses With Supportive Evidence. <b>Endometrial Carcinoma:</b> Condition of approval and criteria were added to Other Uses With Supportive Evidence. <b>Vaginal Cancer:</b> Condition of approval and criteria were added to Other Uses With Supportive Evidence. <b>Vulvar Cancer:</b> Condition of approval and criteria were added to Other Uses With Supportive Evidence.	06/19/2024
Annual Revision	No criteria changes.	06/18/2025

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group.© 2025 The Cigna Group.